Concepts (57)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Social Media | 2 | 2018 | 112 | 0.820 |
Why?
|
| Asthma | 3 | 2017 | 1051 | 0.690 |
Why?
|
| Allergy and Immunology | 1 | 2018 | 17 | 0.570 |
Why?
|
| Conjunctivitis, Allergic | 2 | 2017 | 9 | 0.550 |
Why?
|
| Hypersensitivity | 1 | 2018 | 166 | 0.510 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2017 | 93 | 0.500 |
Why?
|
| Drugs, Investigational | 1 | 2014 | 38 | 0.410 |
Why?
|
| Calcineurin Inhibitors | 1 | 2014 | 53 | 0.410 |
Why?
|
| Rhinitis, Allergic | 1 | 2014 | 52 | 0.410 |
Why?
|
| Cyclosporine | 1 | 2014 | 242 | 0.390 |
Why?
|
| Cell Phone | 1 | 2012 | 38 | 0.380 |
Why?
|
| Tacrolimus | 1 | 2014 | 373 | 0.380 |
Why?
|
| Text Messaging | 1 | 2012 | 35 | 0.370 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 1021 | 0.350 |
Why?
|
| Adolescent Behavior | 1 | 2012 | 115 | 0.350 |
Why?
|
| Health Behavior | 1 | 2012 | 191 | 0.340 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 995 | 0.290 |
Why?
|
| Immunologic Factors | 1 | 2009 | 175 | 0.280 |
Why?
|
| Anti-Allergic Agents | 2 | 2017 | 38 | 0.220 |
Why?
|
| Administration, Ophthalmic | 3 | 2017 | 8 | 0.160 |
Why?
|
| Olopatadine Hydrochloride | 2 | 2017 | 6 | 0.160 |
Why?
|
| Education, Professional | 1 | 2018 | 2 | 0.150 |
Why?
|
| Congresses as Topic | 1 | 2018 | 125 | 0.140 |
Why?
|
| Interleukin-5 | 1 | 2017 | 36 | 0.140 |
Why?
|
| Histamine H1 Antagonists | 1 | 2017 | 39 | 0.130 |
Why?
|
| Eosinophilia | 1 | 2017 | 88 | 0.130 |
Why?
|
| Health Personnel | 1 | 2018 | 241 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 378 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 170 | 0.100 |
Why?
|
| Anaphylaxis | 1 | 2013 | 33 | 0.100 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 155 | 0.100 |
Why?
|
| Humans | 9 | 2018 | 95800 | 0.100 |
Why?
|
| Inventions | 1 | 2012 | 14 | 0.100 |
Why?
|
| Clinical Trials as Topic | 3 | 2017 | 1166 | 0.090 |
Why?
|
| Conjunctivitis | 1 | 2011 | 6 | 0.090 |
Why?
|
| Dibenzoxepins | 1 | 2011 | 5 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1981 | 0.090 |
Why?
|
| Inflammation | 1 | 2017 | 1063 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2017 | 9167 | 0.090 |
Why?
|
| Internet | 1 | 2012 | 340 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1791 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 933 | 0.080 |
Why?
|
| Receptors, Cytokine | 1 | 2009 | 30 | 0.080 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2009 | 126 | 0.080 |
Why?
|
| Rhinitis | 1 | 2011 | 186 | 0.080 |
Why?
|
| Toll-Like Receptors | 1 | 2009 | 101 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2014 | 766 | 0.070 |
Why?
|
| Cytokines | 1 | 2009 | 871 | 0.060 |
Why?
|
| Administration, Intranasal | 2 | 2017 | 140 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2017 | 686 | 0.050 |
Why?
|
| Adult | 2 | 2017 | 28578 | 0.040 |
Why?
|
| Adolescent | 1 | 2012 | 9873 | 0.040 |
Why?
|
| Ophthalmic Solutions | 1 | 2017 | 14 | 0.030 |
Why?
|
| Animals | 1 | 2014 | 28889 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2011 | 84 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1965 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1096 | 0.020 |
Why?
|